Oral XXXX for Parotid Infantile @entity2695 .

@entity1169 @entity1 @entity5 @entity2695
UNASSIGNED: The aim of our study was to assess the efficacy and safety of oral @entity1169 for the treatment of parotid infantile @entity2695 . Between October 2009 and January 2013, @entity1169 was given orally to 30 @entity1 with proliferating @entity2695 at a dose of 1.0 to 1.5 mg/kg per day in our department. The @entity1 included 12 male @entity1 and 18 female @entity1 , aged between 2 and 13 months, with a median of 5.9 months. The lesions were located in the parotid region and measured from 1.5 cm * 2 cm * 0.5 cm to 6 cm * 8 cm * 3 cm in volume. Oral @entity1169 was administered once daily for a mean duration of 22.7 weeks (range, 14-32 wk). Follow-up times were from 1 to 10 months (median, 6.4 mo). Changes in the color and size of the @entity5 were recorded using hemisphere measurements and digital photographs. The treatment results were scored according to a 4-point scale. Overall response was graded scale 4 (excellent) in 18 @entity1 , scale 3 (good) in 11 @entity1 , scale 2 (moderate) in 1 @entity1 , and scale 1 (poor) in none. No major collateral effects and rebounds were observed in any of the @entity1 . Oral @entity1169 was a well-tolerated and effective treatment with mild adverse effects for parotid infantile @entity2695 .
